Literature DB >> 27429715

Could there be light at the end of the tunnel? Mesocaval shunting for refractory esophageal varices in patients with contraindications to transjugular intrahepatic portosystemic shunt.

Jessica Davis1, Albert K Chun1, Marie L Borum1.   

Abstract

Cirrhotic patients with recurrent variceal bleeds who have failed prior medical and endoscopic therapies and are not transjugular intrahepatic portosystemic shunt candidates face a grim prognosis with limited options. We propose that mesocaval shunting be offered to this group of patients as it has the potential to decrease portal pressures and thus decrease the risk of recurrent variceal bleeding. Mesocaval shunts are stent grafts placed by interventional radiologists between the mesenteric system, most often the superior mesenteric vein, and the inferior vena cava. This allows flow to bypass the congested hepatic system, reducing portal pressures. This technique avoids the general anesthesia and morbidity associated with surgical shunt placement and has been successful in several case reports. In this paper we review the technique, candidate selection, potential pitfalls and benefits of mesocaval shunt placement.

Entities:  

Keywords:  Esophageal and gastric varices; Gastrointestinal hemorrhage; Portal hypertension; Surgical portacaval shunt; Transjugular intrahepatic portasystemic shunt

Year:  2016        PMID: 27429715      PMCID: PMC4937167          DOI: 10.4254/wjh.v8.i19.790

Source DB:  PubMed          Journal:  World J Hepatol


  19 in total

1.  Intravascular ultrasound-guided mesocaval shunt creation in patients with portal or mesenteric venous occlusion.

Authors:  Richard Hong; Riaz S Dhanani; John D Louie; Daniel Y Sze
Journal:  J Vasc Interv Radiol       Date:  2012-01       Impact factor: 3.464

2.  Transvenous creation of a mesocaval shunt: report of use in the management of extrahepatic portal vein occlusion.

Authors:  John M Moriarty; Nima Kokabi; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2012-04       Impact factor: 3.464

3.  Liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2016-01       Impact factor: 8.086

Review 4.  Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis.

Authors:  S Khan; C Tudur Smith; P Williamson; R Sutton
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis.

Authors:  L Laine; D Cook
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

6.  Percutaneous Mesocaval Shunt Creation in a Patient with Chronic Portal and Superior Mesenteric Vein Thrombosis.

Authors:  Zachary L Bercu; Sachin B Sheth; Amir Noor; Robert A Lookstein; Aaron M Fischman; F Scott Nowakowski; Edward Kim; Rahul S Patel
Journal:  Cardiovasc Intervent Radiol       Date:  2014-09-05       Impact factor: 2.740

Review 7.  Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem.

Authors:  Guadalupe Garcia-Tsao; Jaime Bosch
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-17       Impact factor: 11.382

8.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.

Authors:  A J Sanyal; A M Freedman; M L Shiffman; P P Purdum; V A Luketic; A K Cheatham
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

9.  Transjugular intrahepatic portosystemic shunt in patients with chronic portal vein occlusion and cavernous transformation.

Authors:  Alexandra Wils; Edwin van der Linden; Bart van Hoek; Peter M T Pattynama
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

10.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.

Authors:  O Riggio; M Merlli; G Pedretti; R Servi; P Meddi; R Lionetti; P Rossi; M Bezzi; F Salvatori; U Ugolotti; F Fiaccadori; L Capocaccia
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

View more
  5 in total

1.  Current Indications and Long-Term Outcomes of Surgical Portosystemic Shunts in Adults.

Authors:  Indrani Sen; Lavanya Yohanathan; Jussi M Kärkkäinen; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2020-05-18       Impact factor: 3.452

Review 2.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

3.  Mesocaval Shunt Creation for Jejunal Variceal Bleeding with Chronic Portal Vein Thrombosis.

Authors:  Ja Kyung Yoon; Man Deuk Kim; Do Yun Lee; Seok Joo Han
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

4.  Treatment of Noncirrhotic Portal Hypertension Secondary to Portal Vein Thrombosis With Endovascular Mesocaval Shunt Creation.

Authors:  Parkpoom Phatharacharukul; Maximilian Pyko; Nabil Fayad
Journal:  Cureus       Date:  2020-05-13

Review 5.  Management of portal hypertension and ascites in polycystic liver disease.

Authors:  Lucas H P Bernts; Joost P H Drenth; Eric T T L Tjwa
Journal:  Liver Int       Date:  2019-09-20       Impact factor: 5.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.